Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Trevena Inc's Competitiveness

Name: Trevena Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Trevena Inc (TRVN) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q3 2024

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/TRVN/competitors                    

                        https://api.csimarket.com/api/v1/companies/TRVN/relationships                    

                        https://api.csimarket.com/api/v1/companies/TRVN/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Trevena Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Trevena inc	-	-	-	Yes
High-Confidence Competitors (6)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

TRVN Stock Performance relative to its Competitors

TRVN Competitors (weighted) Percent change over the selected range

Trevena Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

High-Confidence
(2 of 3)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Trevena inc	-	-
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (3)	40.4%	63.2%
Similar-Size Competitors (0)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Trevena Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

TRVN Stock Performance relative to High-Confidence Competitors

TRVN High-Confidence Competitors (equal-weighted, 7) Percent change over the selected range

Trevena Inc's Comment on Competition and Industry Peers

The competitive landscape for OLINVYK includes products in mid- and late-stage clinical development targeting the treatment of moderate-to-severe acute pain. Avenue Therapeutics, Inc. is developing an intravenous version of the generic opioid tramadol for this indication. The company competes with major pharmaceutical, specialty pharmaceutical, and biotechnology firms, as well as academic institutions, governmental agencies, and public and private research organizations. Competitors may possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry mergers and acquisitions may further concentrate resources among fewer competitors. Additionally, smaller or early-stage companies may also present significant competition.

Competitor data is not yet available for Trevena Inc.

Trevena Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.

Competitor	Basis	Confidence	Active	Sources
AcelRx Pharmaceuticals, Inc.	Named by the company	85%	2022 to 2026	3
DURECT Corporation	Named by the company	85%	2022 to 2026	3
Cara Therapeutics Inc.	Named by the company	85%	2022 to 2026	3
Pacira Pharmaceuticals, Inc.	Named by the company	85%	2022 to 2026	3
Avenue Therapeutics, Inc.	Named by the company	85%	2022 to 2026	3
Heron Therapeutics, Inc.	Named by the company	85%	2022 to 2026	3
Cumberland Pharmaceuticals	Named by the company	85%	2022 to 2026	3
Mallinckrodt plc	Named by the company	85%	2022 to 2026	3
Baudax Bio, Inc.	Named by the company	85%	2022 to 2026	3
Innocoll Holdings plc	Named by the company	85%	2022 to 2026	3

Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Trevena Inc's named competitors require a Commercial License.

Unlock Commercial Access

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.